Addressing cost-related barriers to prescription drug use in Canada

CMAJ. Canadian Medical Association Journal

Volumn 186, Issue 4, 2014, Pages 276-280

  Tang, Karen L ^a,b   Ghali, William A ^a,b   Manns, Braden J ^a,b  

^a Departments of Critical Care Medicine   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; METOPROLOL;

ARTICLE; AWARENESS; CANADA; DRUG COST; DRUG EFFICACY; DRUG SAFETY; GOVERNMENT; HEALTH CARE SYSTEM; HEALTH INSURANCE; HEALTH SERVICE; HEART FAILURE; HEART INFARCTION; HOUSEHOLD; HUMAN; MEDICAID; PATENT; PATIENT EDUCATION; PHYSICIAN ATTITUDE; PRESCRIPTION; SOCIAL BEHAVIOR;

CANADA; DRUG COSTS; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MEDICATION ADHERENCE; PRESCRIPTION DRUGS;

EID: 84895800774     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.121637     Document Type: Article

References (33)

1. Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med 2011; 365:2088-97.
2. Kondro W. The fiendish puzzle of health inequities. CMAJ 2012; 184:1456-7.
3. Law MR, Cheng L, Dhalla IA, et al. The effect of cost on adherence to prescription medications in Canada. CMAJ 2012; 184: 297-302.
4. Barriers to care for people with chronic health conditions: summary report. Calgary (AB): Interdisciplinary Chronic Disease Collaboration; 2013:6.
5. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 2001;285:421-9.
6. Gagnon M, Hébert G. The economic case for universal pharmacare. Ottawa (ON): Canadian Centre for Policy Alternatives; 2010.
7. Generic drugs in Canada: international price comparisons and potential cost savings. Ottawa (ON): Patented Medicine Prices Review Board; 2011. Available: www.pmprb-cepmb.gc.ca /english/view.asp?x=1562&mid=1436 (accessed 2012 Jan. 9).
8. Kapur V, Basu K. Drug coverage in Canada: Who is at risk? Health Policy 2005;71:181-93.
9. Demers V, Melo M, Jackevicius C, et al. Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures. CMAJ 2008;178:405-9.
10. Daw JR, Morgan SG. Stitching the gaps in the Canadian public drug coverage patchwork: a review of provincial pharmacare policy changes from 2000 to 2010. Health Policy 2012;104:19-26.
11. Aaserud M, Dahlgren AT, Kosters JP, et al. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst Rev 2006;(2):CD005979.
12. Schneeweiss S. Reference drug programs: effectiveness and policy implications. Health Policy 2007;81:17-28.
13. Anis A, Harvard S, Marra C. Ontario's plunging price-caps on generics: deeper dives may drown some drugs. Open Med 2011; 5: e149-52.
14. Government of Alberta. Albertans to benefit from reduced prices for existing generic drugs [press release]. Edmonton (AB): Health and Wellness; 2010. Available: http://alberta.ca /acn /201001 /277267697CCF8-C8B8-B2D6- D4419AFAE7D72E85.html (accessed 2012 Mar. 16).
15. Lunn S. Provinces reach deal to save on 6 generic drugs. Toronto (ON): CBC News; 2013. Available: www.cbc.ca/news/canada /story 2013/01/18/pol-generic- drugs-provinces-wall-ghiz.html (ac-cessed 2013 Jan. 24).
16. Gatesman ML, Smith TJ. The shortage of essential chemotherapy drugs in the United States. N Engl J Med 2011;365:1653-5.
17. Reichert S, Simon T, Halm EA. Physicians' attitudes about prescribing and knowledge of the costs of common medications. Arch Intern Med 2000;160:2799-803.
18. Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a systematic review. PLoS Med 2007;4:e283.
19. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-90.
20. Alberta Health and Wellness Drug Benefit List. Edmonton (AB): Alberta Health; 2012.
21. Alexander GC, Casalino LP, Meltzer DO. Patient-physician communication about out-of-pocket costs. JAMA 2003;290: 953-8.
22. Alexander GC, Casalino LP, Tseng CW, et al. Barriers to patient-physician communication about out-of-pocket costs. J Gen Intern Med 2004;19:856-60.
23. Choudhry NK, Rosenthal MB, Milstein A. Assessing the evidence for value-based insurance design. Health Aff (Millwood) 2010; 29:1988-94.
24. Allan GM, Innes GD. Do family physicians know the costs of medical care? Survey in British Columbia. Can Fam Physician 2004; 50:263-70.
25. Frazier LM, Brown JT, Divine GW, et al. Can physician education lower the cost of prescription drugs? A prospective, controlled trial. Ann Intern Med 1991;115:116-21.
26. Guterman JJ, Chernof BA, Mares B, et al. Modifying provider behavior: a low-tech approach to pharmaceutical ordering. J Gen Intern Med 2002;17:792-6.
27. McMullin ST, Lonergan TP, Rynearson CS, et al. Impact of an evidence-based computerized decision support system on primary care prescription costs. Ann Fam Med 2004;2:494-8.
28. Fretheim A, Aaserud M, Oxman AD. Rational prescribing in primary care (RaPP): economic evaluation of an intervention to improve professional practice. PLoS Med 2006;3:e216.
29. Romanow RJ. Building on values: the future of health care in Canada. Ottawa (ON): Commission on the Future of Health Care in Canada; 2002.
30. Phillips K. Catastrophic drug coverage in Canada. Ottawa (ON): Library of Parliament; 2009.
31. Thomson S, Osborn R, Squires D, et al. International profiles of health care systems, 2012. New York (NY): The Commonwealth Fund; 2012.
32. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007;(4):CD005454.
33. Wiffen P, Collins S, McQuay H, et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev 2005; (3): CD001133.